Bioceres Crop Solutions Gestion
Gestion contrôle des critères 0/4
Le PDG Bioceres Crop Solutions est Federico Trucco, nommé en Jun2011, a un mandat de 14.92 ans. détient directement 0.59% des actions de la société, d'une valeur de $ 155.65K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.3 ans et 2.2 ans.
Informations clés
Federico Trucco
Directeur général
n/a
Rémunération totale
| Pourcentage du salaire du PDG | n/a |
| Durée du mandat du directeur général | 14.9yrs |
| Propriété du PDG | 0.6% |
| Durée moyenne d'occupation des postes de direction | 1.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.2yrs |
Mises à jour récentes de la gestion
Recent updates
Article d’analyse • Feb 10
Investors Don't See Light At End Of Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Tunnel And Push Stock Down 54%
To the annoyance of some shareholders, Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shares are down a considerable 54...
Mise à jour du récit • Dec 17
BIOX: Portfolio Recapitalization Progress Will Eventually Overcome Argentina Liquidity Headwinds
Analysts have trimmed their price target on Bioceres Crop Solutions by roughly $0.10 per share, citing heightened Argentina-related liquidity volatility and increased uncertainty around the company’s portfolio recapitalization efforts. Analyst Commentary Analysts acknowledge that Bioceres retains a differentiated portfolio and strategic exposure to key agricultural markets, but sentiment has turned more cautious as near term risks have become more prominent in their valuation work.Mise à jour du récit • Dec 03
BIOX: Next Generation Product Pipeline Will Offset Argentina Liquidity Pressures
Analysts have trimmed their price target on Bioceres Crop Solutions to around $2.25 from approximately $3.63, reflecting concerns over Argentina related liquidity pressures and portfolio recapitalization challenges, even as they continue to see long term value in the company’s next generation product pipeline. Analyst Commentary Street research on Bioceres Crop Solutions reflects a mixed backdrop, with liquidity concerns and execution risks in Argentina offset by continued confidence in the long term earnings power of its next generation product portfolio.Mise à jour du récit • Nov 19
BIOX: Portfolio Recapitalization Will Overcome Argentina Liquidity Pressure Ahead
The analyst price target for Bioceres Crop Solutions was revised downward from $3.75 to $3.63. Analysts cited increased pressure from liquidity concerns and recent portfolio challenges as key factors for the adjustment.Article d’analyse • Nov 17
Is Bioceres Crop Solutions (NASDAQ:BIOX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Mise à jour du récit • Nov 02
BIOX: Recovery From Argentina Volatility Will Drive Future Upside Potential
Analysts have lowered their fair value price target for Bioceres Crop Solutions from $4.17 to $3.75 per share. They cite concerns about Argentina's economic volatility, recent earnings shortfalls, and increased hurdles to the company's portfolio strategy.Article d’analyse • Oct 30
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shareholders are no doubt pleased to see that the share price has bounced...Mise à jour du récit • Oct 18
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have revised their price target for Bioceres Crop Solutions downward from $8 to $5, citing weaker-than-expected Q4 results and leadership transitions. However, they continue to highlight potential in the company’s pipeline for future value creation.Mise à jour du récit • Oct 04
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have lowered their price target for Bioceres Crop Solutions from $8 to $5, citing weaker-than-expected Q4 results and concerns over executive turnover. However, they continue to see long-term value in the company's innovation pipeline.Article d’analyse • Sep 15
The Market Doesn't Like What It Sees From Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Revenues Yet As Shares Tumble 31%
Unfortunately for some shareholders, the Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has dived 31% in the...Seeking Alpha • Sep 09
Bioceres Crop Solutions: Waiting For Gross Profit To Turn (Downgrade)
Summary Downgrade Bioceres Crop Solutions Corp. to Hold due to Argentina's volatile currency, credit constraints, and a challenging shift in the seed sales model. Recent results show sharply lower revenues, deeper losses, but disciplined cash management, and a focus on cost reductions going forward. Valuation sits at 3.5x gross profit and 8.5–11x EV/EBITDA, but earnings risk and potential dilution remain high. If cost cuts and inventory normalization drive EBITDA recovery, I may reconsider BIOX stock, but for now, patience is warranted. Read the full article on Seeking AlphaArticle d’analyse • Aug 01
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Not Doing Enough For Some Investors As Its Shares Slump 25%
The Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has fared very poorly over the last month, falling by a...Article d’analyse • Jul 22
Bioceres Crop Solutions (NASDAQ:BIOX) Use Of Debt Could Be Considered Risky
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Apr 04
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Mar 07
Bioceres Crop Solutions' (NASDAQ:BIOX) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) was disappointing to investors...Article d’analyse • Mar 05
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Might Not Be As Mispriced As It Looks After Plunging 41%
The Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Feb 13
Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Summary Bioceres Crop Solutions Corp. reported a disappointing Q2 2025 with revenues down 24%, driven by Argentina's economic crisis, despite improved international sales. BIOX stock is down 62% year-over-year, and I maintain a Hold rating due to concerns about the company's ability to turn around. The shift to a licensing model for HB4 technology and R&D cuts may improve short-term finances but pose long-term risks. Despite a lower valuation, Bioceres' financial risks and management's past decisions make it unattractive until more data on turnaround effectiveness is available. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Summary Bioceres' 1Q25 results were challenging due to adverse weather in Argentina, affecting crop nutrition, protection, and seeds, but potential recovery is expected in 2Q25. BIOX has depreciated significantly, now trading at $6.7 per share, with a market cap of $400 million, making it a more interesting Hold. Despite some improvements, HB4 commercialization remains underwhelming, and financial risks persist, warranting caution before investing in potential developments. Valuation is approaching reasonable levels, but the company's execution, financial risk, and lack of clear reporting keep me on the sidelines for now. Read the full article on Seeking AlphaArticle d’analyse • Sep 28
Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper
Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shareholders that were waiting for something to happen have been dealt a...
Nouveau récit • Sep 18
HB4 Wheat's US Approval Sparks Global Expansion And Profit Growth Surge
Approval of HB4 Wheat in the US highlights significant expansion and revenue opportunities, enhancing global acceptance and credibility of HB4 technology.Seeking Alpha • Sep 17
Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Summary Bioceres' 4Q24 results disappointed, with flat profitability and a 15% stock drop, driven by a bear market in agricultural commodities and commercialization challenges for HB4 products. The company's debt rose, particularly short term, with unclear maturity risks, and profitability challenges persisted despite top-line growth. Bioceres is shifting tactics for HB4, reducing the priority of its identity-protected program to manage working capital and focusing more on its bio solutions segment. Given low earnings yields, high debt, and market volatility, I rate Bioceres as a Hold, doubting its ability to achieve necessary growth for fair valuation. Read the full article on Seeking AlphaArticle d’analyse • Aug 03
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Mar 23
Bioceres Needs To Add Clarity Around Borrowings
Summary Bioceres is an agricultural supply company with growth potential in seed genetics and biopesticides markets. The company's 2Q24 results showed revenue growth and stable cost structure, leading to profitability. These were expected, given the Argentinian drought in 2023. Concerns remain about the company's high debt maturities and lack of clarity on its debt and refinancing plans. The company's valuation is that of a high growth company, and yet Bioceres is not showing a growth trend. Read the full article on Seeking AlphaArticle d’analyse • Feb 03
Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Oct 04
Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Jun 21
Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Bioceres Crop Solutions Corp.'s ( NASDAQ:BIOX ) price-to-sales (or "P/S") ratio of 2x may not look like an appealing...Article d’analyse • May 09
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 06
Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Summary Corporate conference season is underway, and one Chemicals company is expected to speak at three events through mid-November. Bioceres Crop Solutions also has an earnings release due out Thursday morning, which should move shares in the near term. The stock has been a strong outperformer this year but has a mixed earnings history. I look to clues from the options market on where the stock might go. It is conference season on Wall Street. Investors must pay close attention to corporate events that might impact the stocks they own. One Materials sector company, a small cap, features three potentially market-moving conferences/forums at which the firm's management team is expected to speak. Often at these gatherings, fresh industry news and trends are presented along with key updates on individual companies. The Materials sector is particularly interesting right now given a slew of macro headwinds impacting both domestic and foreign firms. Weather-related trends are also constantly in the news this summer. One Argentina-based Chemicals stock has been resilient in the face of so much uncertainty from interest rates to currencies to climate change. According to CFRA Research, Bioceres Crop Solutions Corp. (BIOX), together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The $846 million market cap Argentina-based Chemicals company in the Materials sector has slightly negative GAAP earnings over the past 12 months and does not pay a dividend, according to The Wall Street Journal. On valuation, earnings are seen as rising this year and next, according to CFRA's forecast. Assuming $0.55 of EPS next year, the stock trades at a high 25-times forward earnings multiple. On a price-to-sales ratio basis, the value is not as high: just 2.3x. For context, according to Koyfin Charts, Bioceres' price-to-sales ratio peaked near 3.0x in mid-2021 with a low of 0.8x in late 2019. Bioceres: Earnings Outlook CFRA BIOX: Historical Price-To-Sales Ratio Trend Koyfin Charts Looking ahead, Wall Street Horizon's data show three events that could influence BIOX shares over the coming two-plus months. Credit Suisse 35th Annual Specialties & Basics Conference 2022: Sept 13-14 Lake Street Capital Markets 6th Annual Best Ideas Growth Conference 2022: Sept 14 S&P Global Crop Science Forum 2022: Nov. 10 There's also a critical Q4 2022 earnings date before the open on Thursday of this week, with an earnings call immediately after results are released. Investors can listen live here. Corporate Event Calendar: Earnings & Conferences Provide Volatility Catalysts Wall Street Horizon The Options AngleSeeking Alpha • Aug 23
Bioceres Crop Solutions jumps 15% after investor pitch
Bioceres Crop Solutions (NASDAQ:BIOX) soared 15% in after hours trading after an investor was bullish on the agriculture company. Bioceres (BIOX) "is a company that I think is going to be the future green Monsanto," Ospraie Management founder and managing partner Dwight Anderson said in an interview with CNBC. "There revenues are exploding. They are exactly in the right position in terms of their customer base and distribution and environmentally friendly products." He expects Bioceres (BIOX) shares may be 2x or 3x higher in the next two years. Ospraie Management is the third largest holder of Bioceres with a 10% stake. Bioceres (BIOX) is scheduled to report fiscal Q4 results on Sept. 8.Article d’analyse • Apr 10
We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Mar 31
Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Bioceres has a profitable segment based on its subsidiary Rizobacter, that sells adjuvants, micro beaded fertilizers and other agricultural solutions. Rizobacter's profits are growing significantly aided by the bull market in agricultural commodities. Bioceres uses Rizobacter's profits and debt to fund its growth strategy based on HB4 technology and further acquisitions. The problem is that HB4's market is difficult to estimate. To increase risk, a high level of debt puts Bioceres in a difficult situation if commodities prices recede. Bioceres continues in the same vein with the proposal to merge with Marrone Bio Innovations.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$67m |
| Dec 31 2025 | n/a | n/a | -US$59m |
| Sep 30 2025 | n/a | n/a | -US$56m |
| Jun 30 2025 | n/a | n/a | -US$55m |
| Mar 31 2025 | n/a | n/a | -US$9m |
| Dec 31 2024 | n/a | n/a | US$2m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | US$4m |
| Mar 31 2024 | n/a | n/a | US$3m |
| Dec 31 2023 | n/a | n/a | US$22m |
| Sep 30 2023 | n/a | n/a | US$14m |
| Jun 30 2023 | n/a | n/a | US$19m |
| Mar 31 2023 | n/a | n/a | US$15m |
| Dec 31 2022 | n/a | n/a | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | n/a | n/a | US$4m |
| Sep 30 2021 | n/a | n/a | US$976k |
| Jun 30 2021 | US$659k | US$131k | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | n/a | n/a | -US$7m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | US$145k | US$145k | US$3m |
| Mar 31 2020 | n/a | n/a | US$20k |
| Dec 31 2019 | n/a | n/a | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$23m |
| Jun 30 2019 | US$155k | US$155k | -US$18m |
Rémunération vs marché: Données insuffisantes pour établir si la rémunération totale de Federico est raisonnable par rapport à des entreprises de taille similaire sur le marché US.
Rémunération et revenus: La rémunération de Federico a augmenté alors que l'entreprise n'est pas rentable.
PDG
Federico Trucco (48 yo)
14.9yrs
Titularisation
US$659,418
Compensation
Dr. Federico Trucco, Ph D., has been Chief Executive Officer of Bioceres Crop Solutions Corp. since June 2011 and served as its Chairman and serves as its Executive Director. He was Head Director of Rizoba...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| General Counsel & Chief Compliance Officer | no data | US$156.00k | pas de données | |
| CEO & Executive Director | 14.9yrs | US$659.42k | 0.59% $ 155.7k | |
| Chief Financial Officer | 1.3yrs | pas de données | pas de données | |
| Principal Accounting Officer | less than a year | pas de données | pas de données | |
| Head of Investor Relations | no data | pas de données | pas de données |
1.3yrs
Durée moyenne de l'emploi
Gestion expérimentée: L'équipe de direction de BIOX n'est pas considérée comme expérimentée (ancienneté moyenne 1.3 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | US$659.42k | 0.59% $ 155.7k | |
| Non-Executive Director | less than a year | pas de données | pas de données | |
| Non-Executive Director | 3.8yrs | pas de données | 0.087% $ 22.9k | |
| Non-Executive Director | less than a year | pas de données | pas de données |
2.2yrs
Durée moyenne de l'emploi
50.5yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la BIOX n'est pas considéré comme expérimenté ( 2.2 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/24 21:23 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bioceres Crop Solutions Corp. est couverte par 2 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Austin Moeller | Canaccord Genuity |